Huang Huang1, Yan Shi2, Jietao Huang3, Xiaohui Wang1, Rui Zhang1, Hong Chen1. 1. Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Chongqing Medical University, China. 2. Chinese Orthopaedics and Traumatology, Heilongjiang University of Chinese Medicine, China. 3. Department of Cardiovascular Medicine, The First Affiliated Hospital of Chongqing Medical University, China.
Abstract
OBJECTIVES: Accumulating evidences demonstrated that circulating tumor cells (CTCs) show significant high concentration in plasma of lung cancer patients compared to control cohorts, suggesting that CTCs may be a promising biomarker for lung cancer. The meta-analysis was used to evaluate potential diagnostic value of CTCs in diagnosing lung cancer. METHODS: Relevant literatures were searched in PubMed, Embase, Cochrane Library, Chinese Biomedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), Technology of Chongqing (VIP), and Wan Fang Data. Summary estimates were used to evaluate CTCs as the diagnostic standard for lung cancer using Meta-DiSc and STATA 12.0 statistical software. RESULTS: This meta-analysis included five studies with a total of 460 lung cancer patients and 239 benign controls. The sensitivity and specificity (95% confidence interval [CI]) of CTCs was 75% (95% CI: 54%-88%) and 92% (95%CI: 82%-97%), respectively. In addition, the area under the summary ROC curve (AUC) was 0.93. CONCLUSION: CTCs is a novel potential biomarker in the diagnosis of lung cancer, and more prospective are needed in the future.
OBJECTIVES: Accumulating evidences demonstrated that circulating tumor cells (CTCs) show significant high concentration in plasma of lung cancerpatients compared to control cohorts, suggesting that CTCs may be a promising biomarker for lung cancer. The meta-analysis was used to evaluate potential diagnostic value of CTCs in diagnosing lung cancer. METHODS: Relevant literatures were searched in PubMed, Embase, Cochrane Library, Chinese Biomedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), Technology of Chongqing (VIP), and Wan Fang Data. Summary estimates were used to evaluate CTCs as the diagnostic standard for lung cancer using Meta-DiSc and STATA 12.0 statistical software. RESULTS: This meta-analysis included five studies with a total of 460 lung cancerpatients and 239 benign controls. The sensitivity and specificity (95% confidence interval [CI]) of CTCs was 75% (95% CI: 54%-88%) and 92% (95%CI: 82%-97%), respectively. In addition, the area under the summary ROC curve (AUC) was 0.93. CONCLUSION: CTCs is a novel potential biomarker in the diagnosis of lung cancer, and more prospective are needed in the future.
Authors: Maria A Papadaki; Afroditi I Sotiriou; Christina Vasilopoulou; Maria Filika; Despoina Aggouraki; Panormitis G Tsoulfas; Christina A Apostolopoulou; Konstantinos Rounis; Dimitrios Mavroudis; Sofia Agelaki Journal: Cancers (Basel) Date: 2020-06-12 Impact factor: 6.639